Mabwell(SH:688062) Xin Lang Cai Jing·2025-12-25 01:38Group 1 - The core viewpoint of the news is that Maiwei Biotechnology has shown significant trading activity and financial performance, with a notable increase in revenue and changes in shareholder composition [1][2]. Group 2 - On December 24, Maiwei Biotechnology's stock rose by 0.99%, with a trading volume of 214 million yuan. The financing buy-in amount was 16.18 million yuan, while the financing repayment was 13.98 million yuan, resulting in a net financing buy-in of 2.20 million yuan. The total financing and securities balance reached 552 million yuan [1]. - The financing balance of Maiwei Biotechnology is 552 million yuan, accounting for 6.79% of its market capitalization, which is above the 60th percentile level over the past year, indicating a high level of financing [1]. - On the same day, the company had no shares repaid in securities lending, with 200 shares sold, amounting to 7,968 yuan. The securities lending balance was 325,600 yuan, which is below the 30th percentile level over the past year, indicating a low level of securities lending [1]. - As of September 30, the number of shareholders of Maiwei Biotechnology was 19,600, an increase of 9.15% from the previous period. The average circulating shares per person decreased by 8.38% to 10,425 shares [2]. - For the period from January to September 2025, Maiwei Biotechnology achieved operating revenue of 566 million yuan, a year-on-year increase of 301.03%. However, the net profit attributable to the parent company was -598 million yuan, reflecting a year-on-year increase of 13.89% [2]. - Among the top ten circulating shareholders as of September 30, 2025, E Fund Medical Healthcare Industry Mixed A ranked as the fourth largest shareholder with 3.17 million shares, marking a new entry. Hong Kong Central Clearing Limited ranked sixth with 2.87 million shares, a decrease of 1.87 million shares from the previous period. Southern CSI 1000 ETF ranked ninth with 2.19 million shares, also a new entry [2].